Novel therapeutics for coronary artery disease from genome-wide association study data

BMC Medical Genomics

Table 1 Selected novel therapeutics suitable for repositioning for CAD

Target	*Drug name	Disease	Action	Status	*Database
CHRM3	Tiotropium	Chronic obstructive pulmonary disease	Antagonist	Approved	TTD
HTR1A	Fluvoxamine	Depressive disorder	Unknown	Unknown	PharmGKB
FLT1	Sorafenib	Advanced renal cell carcinoma	Inhibitor	Launched	TTD
ABAT	Vigabatrin	Epilepsy	Inhibitor	Approved	TTD
GRIK2	Metharbital	Epilepsy	Antagonist	Approved	DrugBank
IL2RB	Aldesleukin	Metastatic renal cell carcinoma	Agonist	Approved	DrugBank
ITGB1	Antithymocyte globulin	Prevention of renal transplant rejection	Unknown	Approved	DrugBank
PDGFRA	Becaplermin	Skin ulcers (from diabetes)	Unknown	Approved	DrugBank
IL2RB	Daclizumab	Prevention of renal transplant rejection	Antibody	Approved	DrugBank
VEGFA	Bevacizumab	Metastatic breast cancer	Unknown	Approved	DrugBank

Selected novel therapeutics suitable for repositioning to develop potential treatment of CAD.
(* These drugs mentioned here are only selected examples because one therapeutic target may be associated with multiple drugs); (* Drug databases mentioned here are only selected examples because one drug-target association may be described in more than one drug database). Abbreviations - PH - Phenotype; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase; CAD - Coronary Artery Disease.

ISSN: 1755-8794